Mark C Chappell Selected Research

angiotensin I (1-7)

12/2020	Association of circulating uric acid and angiotensin-(1-7) in relation to higher blood pressure in adolescents and the influence of preterm birth.
1/2020	Lower urinary α-Klotho is associated with lower angiotensin-(1-7) and higher blood pressure in young adults born preterm with very low birthweight.
1/2019	Obesity is Associated with Higher Blood Pressure and Higher Levels of Angiotensin II but Lower Angiotensin-(1-7) in Adolescents Born Preterm.
10/2018	Association between preterm birth and the renin-angiotensin system in adolescence: influence of sex and obesity.
10/2017	Stabilization of Angiotensin-(1-7) by key substitution with a cyclic non-natural amino acid.
1/2017	Angiotensin-(1-7)-dependent vasorelaxation of the renal artery exhibits unique angiotensin and bradykinin receptor selectivity.
12/2014	Angiotensin-(1-7) abolishes AGE-induced cellular hypertrophy and myofibroblast transformation via inhibition of ERK1/2.
2/2013	Response to Angiotensin-(1-7) and Bradykinin in Baroreceptor Reflex Sensitivity in Hypertension.
7/2010	Angiotensin-(1-7) prevents diabetes-induced attenuation in PPAR-gamma and catalase activities.
6/2010	Inhibition of angiotensin-converting enzyme 2 exacerbates cardiac hypertrophy and fibrosis in Ren-2 hypertensive rats.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mark C Chappell Research Topics

Disease

34	Hypertension (High Blood Pressure) 01/2021 - 06/2002
10	Fibrosis (Cirrhosis) 01/2017 - 10/2007
9	Proteinuria 11/2014 - 11/2006
8	Inflammation (Inflammations) 01/2022 - 01/2010
7	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 12/2011
6	Hypertrophy 12/2014 - 10/2007
5	Body Weight (Weight, Body) 08/2009 - 10/2002
4	Obesity 12/2020 - 10/2018
3	Heart Failure 01/2019 - 10/2003
3	Overweight 01/2019 - 10/2018
3	Ventricular Remodeling 03/2014 - 01/2006
3	Cardiomegaly (Heart Hypertrophy) 06/2010 - 10/2003
2	COVID-19 01/2021 - 01/2020
2	Premature Birth (Birth, Premature) 12/2020 - 01/2019
2	Pre-Eclampsia (Preeclampsia) 09/2015 - 02/2010
2	Diabetic Nephropathies (Diabetic Nephropathy) 12/2014 - 01/2010
2	Hypotension (Low Blood Pressure) 06/2011 - 04/2004
2	Ischemia 05/2011 - 08/2005
2	Polyuria 11/2005 - 04/2004
1	Birth Weight (Birth Weights) 01/2020
1	Insulin Resistance 01/2018
1	Neoplasms (Cancer) 10/2017
1	Vascular System Injuries 04/2016
1	Diastolic Heart Failure 03/2014
1	Heart Diseases (Heart Disease) 03/2014
1	Primary Ovarian Insufficiency 03/2014
1	Premature Obstetric Labor (Premature Labor) 06/2013
1	Albuminuria 06/2012
1	Fetal Growth Retardation (Intrauterine Growth Retardation) 11/2011
1	Gestational Weight Gain 11/2011
1	Atrial Fibrillation 01/2011
1	Hyperglycemia 07/2010

Drug/Important Bio-Agent (IBA)

14	Angiotensin IIIBA 01/2021 - 06/2002
13	angiotensin I (1-7)IBA 12/2020 - 10/2003
10	Estrogens (Estrogen)FDA Link 04/2016 - 10/2003
10	SaltsIBA 04/2016 - 06/2002
8	AngiotensinsIBA 01/2021 - 10/2002
7	Angiotensin-Converting Enzyme 2IBA 01/2021 - 06/2002
7	ReninIBA 12/2020 - 01/2008
6	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 03/2012 - 08/2005
5	AldosteroneIBA 12/2020 - 01/2008
5	SodiumIBA 12/2020 - 11/2006
5	CreatinineIBA 01/2019 - 11/2005
4	Peptides (Polypeptides)IBA 10/2018 - 11/2005
3	EnzymesIBA 01/2020 - 06/2002
3	Proteins (Proteins, Gene)FDA Link 01/2020 - 01/2008
3	SteroidsIBA 06/2013 - 01/2008
3	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 03/2012 - 08/2009
2	Prorenin ReceptorIBA 01/2021 - 01/2008
2	AlbuminsIBA 01/2019 - 12/2014
2	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2019 - 01/2019
2	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2019 - 05/2011
2	Hormones (Hormone)IBA 10/2017 - 06/2011
2	Peptide Hydrolases (Proteases)FDA Link 10/2017 - 02/2014
2	GlucocorticoidsIBA 11/2014 - 06/2013
2	Estrogen Receptor alphaIBA 03/2014 - 08/2009
2	Nitric Oxide Synthase (NO Synthase)IBA 03/2014 - 06/2012
2	Betamethasone (Celestone)FDA Link 06/2013 - 02/2012
2	NADPH Oxidases (NAD(P)H oxidase)IBA 06/2012 - 07/2010
2	AngiotensinogenIBA 06/2012 - 02/2010
2	Estrogen ReceptorsIBA 10/2011 - 05/2011
2	Drinking WaterIBA 05/2011 - 10/2002
2	omapatrilatIBA 10/2002 - 06/2002
1	Retinal Pigments (Pigments, Visual)IBA 01/2022
1	Retinaldehyde (Retinal)IBA 01/2022
1	Uric Acid (Urate)IBA 12/2020
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2020
1	tempolIBA 01/2019
1	Adrenergic Agents (Adrenergic Drugs)IBA 01/2019
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2019
1	TEMPOIBA 01/2019
1	DiureticsIBA 01/2019
1	Phenylephrine (Neo-Synephrine)FDA LinkGeneric 04/2016
1	Glucose (Dextrose)FDA LinkGeneric 12/2014
1	Pyruvaldehyde (Methylglyoxal)IBA 12/2014
1	4- ethoxymethylene- 2- phenyl- 2- oxazoline- 5- one (phOx)IBA 11/2014
1	GTP-Binding Proteins (G-Protein)IBA 03/2014
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 03/2014
1	BradykininIBA 02/2013
1	Protein Isoforms (Isoforms)IBA 06/2012
1	Messenger RNA (mRNA)IBA 06/2012
1	Type 1 Angiotensin ReceptorIBA 03/2012
1	Gonadal Steroid Hormones (Sex Hormones)IBA 12/2011
1	4-hydroxy-2-nonenal (4-hydroxynonenal)IBA 10/2011
1	8-epi-prostaglandin F2alphaIBA 10/2011
1	Hydrocortisone (Cortisol)FDA LinkGeneric 06/2011
1	Adrenocorticotropic Hormone (ACTH)FDA Link 06/2011
1	Captopril (Capoten)FDA LinkGeneric 05/2011
1	Hydralazine (Apresoline)FDA LinkGeneric 05/2011
1	Dimethyl Sulfoxide (DMSO)FDA LinkGeneric 11/2010
1	acetovanillone (apocynin)IBA 07/2010
1	CatalaseIBA 07/2010
1	PPAR gammaIBA 07/2010
1	Streptozocin (Streptozotocin)FDA Link 07/2010
1	CollagenIBA 06/2010

Therapy/Procedure

8	Therapeutics 01/2021 - 03/2008
1	Contraindications 03/2014
1	Estrogen Replacement Therapy 03/2014
1	Hormone Replacement Therapy (Therapy, Hormone Replacement) 12/2011
1	Operative Surgical Procedures 01/2011